AU2013203367B2 - Low frequency glatiramer acetate therapy - Google Patents

Low frequency glatiramer acetate therapy Download PDF

Info

Publication number
AU2013203367B2
AU2013203367B2 AU2013203367A AU2013203367A AU2013203367B2 AU 2013203367 B2 AU2013203367 B2 AU 2013203367B2 AU 2013203367 A AU2013203367 A AU 2013203367A AU 2013203367 A AU2013203367 A AU 2013203367A AU 2013203367 B2 AU2013203367 B2 AU 2013203367B2
Authority
AU
Australia
Prior art keywords
day
glatiramer acetate
multiple sclerosis
human patient
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013203367A
Other versions
AU2013203367A1 (en
AU2013203367C1 (en
Inventor
Ety Klinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61005614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013203367(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2010284666A external-priority patent/AU2010284666B2/en
Priority claimed from AU2013201328A external-priority patent/AU2013201328B2/en
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Priority to AU2013203367A priority Critical patent/AU2013203367C1/en
Publication of AU2013203367A1 publication Critical patent/AU2013203367A1/en
Publication of AU2013203367B2 publication Critical patent/AU2013203367B2/en
Application granted granted Critical
Publication of AU2013203367C1 publication Critical patent/AU2013203367C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

LOW FREQUENCY GLATIRAMER ACETATE THERAPY A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.

Description

- 1 LOW FREQUENCY GLATIRAMER ACETATE THERAPY This application is a divisional application pursuant to 5 Section 79B of the Patents Act 1990 of Australian Patent Application No. 2013201328 which is a divisional application of Australian Patent Application No. 2010284666 which corresponds to International Application No. PCT/US2010/002283 filed August 19, 2010, which claims priority of U.S. 10 Provisional Applications Nos. 61/337,612, filed February 11, 2010 and 61/274,687, filed August 20, 2009, the contents of each of which are hereby incorporated by reference in their entirety. 15 Throughout this application various publications are referenced by their full citations. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention 20 pertains. BACKGROUND OF THE INVENTION Multiple Sclerosis (MS) is a chronic, debilitating disease of the central nervous system (CNS) . MS has also been classified 25 as an autoimmune disease. MS disease activity can be monitored by magnetic resonance imaging (MRI) of the brain, accumulation of disability, as well as rate and severity of relapses. There are five main forms of multiple sclerosis: 30 1) Benign Multiple Sclerosis: Benign multiple sclerosis is a retrospective diagnosis which is characterized by 1-2 exacerbations with complete recovery, - 2 no lasting disability and no disease progression for 10-15 years after the initial onset. Benign multiple sclerosis may, however, progress into other forms of multiple sclerosis. 5 2) Relapsing-Remitting Multiple Sclerosis (RRMS) : Patients suffering from RRMS experience sporadic exacerbations or relapses, as well as periods of remission. Lesions and evidence of axonal loss may or may not be visible on MRI for patients with RRMS. 10 3) Secondary Progressive Multiple Sclerosis (SPMS): SPMS may evolve from RRMS. Patients afflicted with SPMS have relapses, a diminishing degree of recovery during remissions, less frequent remissions and more pronounced neurological 15 deficits than RRMS patients. Enlarged ventricles, which are markers for atrophy of the corpus callosum, midline center and spinal cord, are visible on MRI of patients with SPMS. 4) Primary Progressive Multiple Sclerosis (PPMS); 20 PPMS is characterized by a steady progression of increasing neurological deficits without distinct attacks or remissions. Cerebral lesions, diffuse spinal cord damage and evidence of axonal loss are evident on the MRI of patients with PPMS. 25 5) Progressive-Relapsing Multiple Sclerosis (PRMS): PRMS has periods of acute exacerbations while proceeding along a course of increasing neurological deficits without remissions. Lesions are evident on MRI of patients suffering from PRMS (Multiple sclerosis: its diagnosis, symptoms, types 30 and stages, 2003, albany.net/.about .tjc/multiple sclerosis.html; What are the Types of Multiple Sclerosis?, 2005, <imaginis.com/multiple-sclerosis/types-of-ms.asp? mode=1>).
- 3 Chronic progressive multiple sclerosis is a term used to collectively refer to SPMS, PPMS, and PRMS (Types of Multiple Sclerosis (MS), 2005, <themcfox.com/multiple-sclerosis/types of-ms/types-of-multi-ple-sclerosis.htm>) . The relapsing forms 5 of multiple sclerosis are SPMS with superimposed relapses, RRMS and PRMS. Glatiramer acetate (GA), a mixture of polypeptides which do not all have the same amino acid sequence, is marketed under 10 the tradename Copaxone@. GA comprises the acetate salts of polypeptides containing L-glutamic acid, L-alanine, L-tyrosine and L-lysine at average molar fractions of 0.141, 0.427, 0.095 and 0.338, respectively. The average molecular weight of Copaxone@ is between 5,000 and 9,000 daltons. ("Copaxone", 15 Physician's Desk Reference, (2005), Medical Economics Co., Inc., (Montvale, N.J.), 3115.) Chemically, glatiramer acetate is designated L-glutamic acid polymer with L-alanine, L lysine, L-tyrosine, acetate (salt). 20 Its structural formula is: (Glu,Ala,Lys,Tyr)x.X CH 3 COOH
(C
5
H
9 NO4-C 3
H
7 NO2-C 6 Hi 4
N
2 02-C 9 HlNO 3 ) x-x CHO CAS-147245-92-9 25 Copaxone@ ("Copaxone", Full Prescribing Information, (February, 2009), FDA Marketing Label) (20mg glatiramer acetate daily injection) is an approved therapy for patients with relapsing remitting multiple sclerosis (RRMS), including 30 patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. GA has also been disclosed for use in the treatment of other autoimmune diseases (U.S. Patent Publication No. 2002/0055466 - 4 Al (R. Aharoni et al.), inflammatory non-autoimmune diseases (U.S. Patent Publication No. 2005/0014694 Al (V. Wee Yong et al.); and U.S. Patent Application No. 2002/0077278 Al, published Jun. 20, 2002 (Young et al.)) and other diseases 5 (U.S. Patent Publication Nos. 2003/0004099 Al and 2002/0037848 Al (Eisenbach-Schwartz, et al.); U.S. Pat. No. 6,514,938 Bl, issued Feb. 4, 2003 (Gad et al.); PCT International Publication No. WO 01/60392, published Aug. 23, 2001 (Gilbert et al.); PCT International Publication No. WO 00/27417, 10 published May 19, 2000 (Aharoni et al.); and PCT International Publication No. WO 01/97846, published Dec. 27, 2001 (Moses et al.). The 20mg/day subcutaneous (s.c.) dose has been shown to reduce 15 the total number of enhancing lesions in MS patients as measured by MRI (G. Comi et al., European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetere on Magnetic Resonance Imaging-Measured Disease Activity and Burden in 20 Patients with Relapsing Multiple Sclerosis, Ann. Neurol. 49:290-297 (2001)). Safety data accumulated for GA in clinical trials shows that the drug product is safe and well tolerated. 25 Disclosed is an effective low frequency dosage regimen of GA administration to patients suffering from a relapsing form of multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with 30 multiple sclerosis.
-5 SUMMARY OF THE INVENTION This invention provides a method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a 5 patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a 0 period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient. This invention also provides a method of alleviating a symptom 5 of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis, said method comprising 0 administering to the human patient three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient. 25 This invention also provides a method of reducing the frequency of relapses in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and has MRI features consistent with multiple sclerosis comprising administering to 30 the human patient a therapeutically effective dosage regimen of three subcutaneous injections of 1 ml of a pharmaceutical - 5A composition comprising 40mg of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection, the regimen being sufficient to reduce the frequency of relapses in the patient. 5 This invention also provides a medicament comprising glatiramer acetate for use in treatment of a human patient who is suffering from relapsing-remitting multiple sclerosis or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis, 0 wherein the medicament is to be administered in a regimen of three subcutaneous injections of a 40mg dose of glatiramer acetate every seven days with at least one day between each subcutaneous injection. This invention also provides a glatiramer acetate for use in a 5 regimen of three subcutaneous injections of a 40mg dose of glatiramer acetate every seven days with at least one day between each subcutaneous injection for treatment of a human patient who is suffering from relapsing-remitting multiple sclerosis or who has experienced a first clinical episode and 0 is at high risk of developing clinically definite multiple sclerosis. This invention also provides a medicament comprising glatiramer acetate for use in treatment of a human patient who is suffering from relapsing-remitting multiple sclerosis or 25 who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis, wherein the medicament comprises a 40mg dose of glatiramer acetate and wherein the medicament is to be administered by subcutaneous injection in a regimen of subcutaneous injections 30 three times every week with at least one day between each -5B subcutaneous injection, and wherein the medicament is a pharmaceutical composition having a pH in the range of 5.5 to 8.5. This invention also provides a glatiramer acetate for use in a 5 regimen of administration, the regimen comprising a 40mg dose of glatiramer acetate administered by subcutaneous injection three times every week with at least one day between each subcutaneous injection for use in treatment of a human patient who is suffering from relapsing-remitting multiple sclerosis 0 or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis, and wherein the glatiramer acetate is administered in a pharmaceutical composition having a pH in the range of 5.5 to 8.5. 5 This invention also provides a method of treatment of a human patient suffering from a relapsing form of multiple sclerosis comprising administration to the human patient of three subcutaneous injections of a 40 mg/ml dose of glatiramer acetate each week so as to treat the human patient. 20 This invention also provides a method of treatment of a human patient suffering from a relapsing form of multiple sclerosis which consists of administering weekly to the human patient on only three days during each week a single subcutaneous injection of a 40mg dose of glatiramer acetate so as to treat 25 the human patient. This invention also provides a method of treatment of a human patient suffering from a relapsing form of multiple sclerosis consisting of subcutaneous injections for at least 6 months with lml of a pharmaceutical composition comprising 40mg of 30 glatiramer acetate on only three days during each week with at -5C least one day without a subcutaneous injection of the pharmaceutical composition between each day on which there is a subcutaneous injection, wherein the pharmaceutical composition is in a prefilled syringe, and wherein the 5 pharmaceutical composition further comprises mannitol and has a pH in the range 5.5 to 7.0. This invention also provides a method of treatment of a human patient who has experienced a first clinical episode suggestive of multiple sclerosis and has at least two MRI 0 lesions suggestive of multiple sclerosis which consists of administering weekly to the human patient on only three days during each week a single subcutaneous injection of a 40mg dose of glatiramer acetate so as to treat the human patient. This invention also provides a method of treatment of a human 5 patient who has experienced a first clinical episode suggestive of multiple sclerosis and has at least two MRI lesions suggestive of multiple sclerosis consisting of subcutaneous injections for at least 6 months with lml of a pharmaceutical composition comprising 40mg of glatiramer 0 acetate on only three days during each week with at least one day without a subcutaneous injection of the pharmaceutical composition between each day on which there is a subcutaneous injection, wherein the pharmaceutical composition is in a prefilled syringe, and wherein the pharmaceutical composition 25 further comprises mannitol and has a pH in the range 5.5 to 7.0. This invention also provides a method of treatment of a human patient suffering from a relapsing form of multiple sclerosis which method is more tolerable than and as effective as 30 administration of 20mg of glatiramer acetate s.c. daily, the -5D method consisting of subcutaneous injections for at least 6 months with 1ml of a pharmaceutical composition comprising 40mg of glatiramer acetate on only three days during each week with at least one day without a subcutaneous injection of the 5 pharmaceutical composition between each day on which there is a subcutaneous injection, wherein the pharmaceutical composition is in a prefilled syringe, and wherein the pharmaceutical composition further comprises mannitol and has a pH in the range 5.5 to 7.0, so as to treat the human patient 0 as effectively as, but more tolerably than, administration of 20mg of glatiramer acetate s.c. daily, wherein the effect is reduction of relapses. This invention also provides a method of reducing the frequency and severity of post injection reactions and of 5 injection site reactions of glatiramer acetate therapy in a human patient suffering from a relapsing form of multiple sclerosis, the method consisting of subcutaneous injections for at least 4 months with lml of a pharmaceutical composition comprising 40mg of glatiramer acetate on only three days 0 during each week with at least one day without a subcutaneous injection of the pharmaceutical composition between each day on which there is a subcutaneous injection, wherein the pharmaceutical composition is in a prefilled syringe, and wherein the pharmaceutical composition further comprises 25 mannitol and has a pH in the range 5.5 to 7.0, so as to reduce the frequency and severity of post injection reactions and of injection site reactions in the human patient relative to administration of 20mg of glatiramer acetate s.c. daily. This invention also provides a method of increasing the 30 tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has -5E experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis which comprises reducing the frequency of subcutaneous injections of a pharmaceutical composition 5 comprising a therapeutically effective dose of glatiramer acetate to three times over a period of seven days with at least one day between every injection. In another embodiment, the therapeutically effective dose of 0 glatiramer acetate is 40mg/ml. This invention also provides a use of glatiramer acetate in the preparation of a medicament for treating relapsing remitting multiple sclerosis in a human patient suffering from 5 relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis wherein the administration pattern of the medicament -6 is three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. 5 This invention additionally provides a use of glatiramer acetate in the preparation of a medicament for treating relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a 0 patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis wherein the medicament is prepared for an administration pattern of three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over 5 a period of seven days with at least one day between every subcutaneous injection. This invention yet also provides a use of glatiramer acetate in the preparation of a medicament for increasing the 0 tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis wherein the administration pattern of the medicament 25 is three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. 30 This invention further provides a use of glatiramer acetate in the preparation of a medicament for increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has -7 experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis wherein the medicament is prepared for an administration pattern of three subcutaneous injections of a 5 therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. This invention provides glatiramer acetate for use in treating 0 relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis by three subcutaneous injections 5 over a period of seven days with at least one day between every subcutaneous injection. This invention also provides glatiramer acetate for use in increasing the tolerability of GA treatment in a human patient 0 suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis by three subcutaneous injections over a period of seven days with at least one day between 25 every subcutaneous injection. This invention also provides a method of increasing the tolerability of Glatiramer acetate (GA) treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and 30 is determined to be at high risk of developing clinically definite multiple sclerosis, said method comprising reducing a frequency of subcutaneous injections from daily subcutaneous - 7A injections of a pharmaceutical composition comprising a 20 mg dose of glatiramer acetate to three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every injection. 5 This invention also provides use of glatiramer acetate in the preparation of a medicament for treating relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be 0 at high risk of developing clinically definite multiple sclerosis wherein the administration pattern of the medicament is three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. 5 This invention also provides use of glatiramer acetate in the preparation of a medicament for treating relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be 0 at high risk of developing clinically definite multiple sclerosis, wherein the medicament is prepared for an administration pattern of three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. 25 This invention also provides use of glatiramer acetate in the preparation of a medicament for increasing the tolerability of Glatiramer acetate (GA) treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to 30 be at high risk of developing clinically definite multiple - 7B sclerosis, wherein the administration pattern of the medicament is three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. 5 This invention also provides use of glatiramer acetate in the preparation of a medicament for increasing the tolerability of Glatiramer acetate (GA) treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to 0 be at high risk of developing clinically definite multiple sclerosis, wherein the medicament is prepared for an administration pattern of three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. 5 This invention also provides glatiramer acetate when used in treating relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically 0 definite multiple sclerosis by three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. This invention also provides glatiramer acetate when used in 25 increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis by three subcutaneous injections 30 of a 40mg dose of glatiramer acetate over a period of seven -7C days with at least one day between every subcutaneous injection. This invention also provides a method of reducing frequency of relapses in a human patient suffering from relapsing-remitting 5 multiple sclerosis, said method comprising administering to the human patient three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. This invention also provides a method of treating a human 0 patient with at least two MRI lesions suggestive of multiple sclerosis who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis, said method comprising administering to the human patient three subcutaneous 5 injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. This invention also provides a medicament comprising a 40mg dose of glatiramer acetate when used in reducing frequency of 20 relapses in a human patient suffering from relapsing-remitting multiple sclerosis, wherein the medicament is to be administered in three subcutaneous injections over a period of seven days with at least one day between each subcutaneous injection. 25 This invention also provides use of glatiramer acetate in a treatment regimen to reduce frequency of relapse in a human patient suffering from relapsing-remitting multiple sclerosis, wherein the treatment regimen comprises three subcutaneous injections of a 40mg dose of glatiramer acetate over a period -7D of seven days with at least one day between each subcutaneous injection. This invention also provides a medicament comprising a 40mg dose of glatiramer acetate when used in treating a human 5 patient with at least two MRI lesions suggestive of multiple sclerosis who has experienced a first clinical episode, wherein the medicament is to be administered in three subcutaneous injections over a period of seven days with at least one day between each subcutaneous injection. 0 This invention also provides use of glatiramer acetate in a treatment regimen to treat a human patient with at least two MRI lesions suggestive of multiple sclerosis who has experienced a first clinical episode, wherein the treatment regimen comprises three subcutaneous injections of a 40mg dose 5 of glatiramer acetate over a period of seven days with at least one day between each subcutaneous injection. This invention also provides a pharmaceutical product consisting of unit dosages in a pattern of three unit dosages each consisting of a prefilled syringe containing 40mg/ml 20 glatiramer acetate and mannitol in a pharmaceutical composition having a pH in the range of 5.5 to 7.0.
- 8 DETAILED DESCRIPTION OF THE INVENTION This invention provides a method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a 5 patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a 10 period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient. In another embodiment, there are three injections for every 15 seven days and there must be at least one day between each injection. In a further embodiment, possible injection schedules include Day 1, Day 3, Day 5; Day 1, Day 3, Day 6; Day 1, Day 3, Day 7; Day 1, Day 4, Day 6; Day 1, Day 4, Day 7; Day 1, Day 5, Day 7; Day 2, Day 4, Day 6; Day 2, Day 4, Day 7; 20 Day 2, Day 5, Day 7; or Day 3, Day 5, Day 7. In an embodiment, alleviating a symptom comprises reducing the frequency of relapses. 25 In yet another embodiment, alleviating a symptom comprises reducing the mean cumulative number of Gd-enhancing lesions in the brain of the patient. In another embodiment, alleviating a symptom comprises 30 reducing the mean number of new T 2 lesions in the brain of the patient.
- 9 In a further embodiment, alleviating a symptom comprises reducing the cumulative number of enhancing lesions on Ti weighted images in the patient. 5 In another embodiment, alleviating a symptom comprises reducing brain atrophy in the patient. In another embodiment, alleviating a symptom comprises increasing the time to a confirmed relapse in the patient. 10 In another embodiment, alleviating a symptom comprises reducing the total number of confirmed relapses in the patient. 15 In another embodiment, alleviating a symptom comprises reducing the progression of MRI-monitored disease activity in the patient. In another embodiment, alleviating a symptom comprises 20 reducing total volume of T 2 lesionsin the patient. In another embodiment, alleviating a symptom comprises reducing the number of new hypointense lesions on enhanced Ti scans in the patient. 25 In another embodiment, alleviating a symptom comprises reducing the total volume of hypointense lesions on enhanced Ti scans in the patient. 30 In another embodiment, alleviating a symptom comprises reducing the level of disability as measured by EDSS Score in the patient.
- 10 In another embodiment, alleviating a symptom comprises reducing the change in EDSS Score in the patient. In another embodiment, alleviating a symptom comprises 5 reducing the change in Ambulation Index in the patient. In another embodiment, alleviating a symptom comprises reducing the level of disability as measured by EuroQoL (EQ5D) questionnaire in the patient. 10 In another embodiment, alleviating a symptom comprises reducing the level of disability as measured by the work productivity and activities impairment - General Health (WPAI GH) questionnaire in the patient. 15 In an additional embodiment, the pharmaceutical composition is in a prefilled syringe for self administration by the patient. In yet another embodiment, the therapeutically effective dose 20 of glatiramer acetate is 40mg/ml. In a further embodiment, the therapeutically effective dose of glatiramer acetate is 40mg/0.75ml. In a further embodiment, the patient has not received 25 glatiramer acetate therapy prior to initiation of the subcutaneous injections. In an embodiment, the pharmaceutical composition is in the form of a sterile solution. 30 In another embodiment, the pharmaceutical composition further comprises mannitol.
- 11 In yet another embodiment, the pharmaceutical composition has a pH in the range of 5.5 to 8.5. 5 In an embodiment, the pharmaceutical composition has a pH in the range of 5.5 to 7.0. In an embodiment the frequency of an immediate post injection reaction or the frequency of an injection site reaction is 10 reduced relative to daily subcutaneous administration of 20mg glatiramer acetate. This invention also provides a method of increasing the tolerability of GA treatment in a human patient suffering from 15 relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis which comprises reducing the frequency of subcutaneous injections of a pharmaceutical composition 20 comprising a therapeutically effective dose of glatiramer acetate to three times over a period of seven days with at least one day between every injection. In another embodiment, increasing the tolerability of GA 25 treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an immediate post injection reaction. In yet another embodiment, the immediate post injection 30 reaction is palpitations, feeling hot, flushing, hot flushes, tachycardia, dyspnoea, chest discomfort, chest pain, non cardiac chest , asthenia, back pain, bacterial infection, chills, cyst, face edema, fever, flu syndrome, infection, injection site erythema, injection site hemorrhage, injection - 12 site induration, injection site inflammation, injection site mass, injection site pain, injection site pruritus, injection site urticaria, injection site welt, neck pain, pain, migrane, syncope, tachycardia, vasodilatation, anorexia, diarrhea, 5 gastroenteritis, gastrointestinal disorder, nausea, vomiting, ecchymosis, peripheral edema, arthralgia, agitation, anxiety, confusion, foot drop, hypertonia, nervousness, nystagmus, speech disorder, tremor, vertigo, bronchitis, dyspnea, laryngismus, rhinitis, erythema, herpes simplex, pruritus, 10 rash, skin nodule, sweating, urticaria, ear pain, eye disorder, dysmenorrheal, urinary urgency, or vaginal moniliasis. In an additional embodiment, increasing the tolerability of GA 15 treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an injection site reaction. In a further embodiment, the injection site reaction is 20 erythema, hemorrhage, induration, inflammation, mass, pain, pruritus, urticaria, or welt that occurs immediately around the site of injection. In an embodiment, a single clinical attack includes a clinical 25 episode of optic neuritis, blurring of vision, diplopia, involuntary rapid eye movement, blindness, loss of balance, tremors, ataxia, vertigo, clumsiness of a limb, lack of coordination, weakness of one or more extremity, altered muscle tone, muscle stiffness, spasms, tingling, paraesthesia, 30 burning sensations, muscle pains, facial pain, trigeminal neuralgia, stabbing sharp pains, burning tingling pain, slowing of speech, slurring of words, changes in rhythm of speech, dysphagia, fatigue, bladder problems (including urgency, frequency, incomplete emptying and incontinence), - 13 bowel problems (including constipation and loss of bowel control), impotence, diminished sexual arousal, loss of sensation, sensitivity to heat, loss of short term memory, loss of concentration, or loss of judgment or reasoning. 5 In another embodiment, prior to administration the patient has at least 1 cerebral lesion detectable by an MRI scan and suggestive of multiple sclerosis. 10 In yet another embodiment, the lesion is associated with brain tissue inflammation, myelin sheath damage or axonal damage. In an additional embodiment, the lesion is a demyelinating white matter lesion visible on brain MRI. 15 In a further embodiment, the white matter lesions are at least 3 mm in diameter. This invention also provides a use of glatiramer acetate in the preparation of a medicament for treating relapsing remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis wherein the administration pattern of the medicament is three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. This invention additionally provides a use of glatiramer acetate in the preparation of a medicament for treating relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a - 14 patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis wherein the medicament is prepared for an administration pattern of three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. This invention yet also provides a use of glatiramer acetate in the preparation of a medicament for increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis wherein the administration pattern of the medicament is three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. This invention further provides a use of glatiramer acetate in the preparation of a medicament for increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis wherein the medicament is prepared for an administration pattern of three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection. This invention provides glatiramer acetate for use in treating relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a - 15 patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis by three subcutaneous injections over a period of seven days with at least one day between every subcutaneous injection. This invention also provides glatiramer acetate for use in increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis by three subcutaneous injections over a period of seven days with at least one day between every subcutaneous injection. DEFINITIONS As used herein, immediate post injection reaction (IRPR) 5 refers to a reaction such as, palpitations, feeling hot, flushing, hot flushes, tachycardia, dyspnoea, chest discomfort, chest pain, and non-cardiac chest pain that occurs immediately following injection. Reactions may also include asthenia, back pain, bacterial infection, chills, cyst, face 10 edema, fever, flu syndrome, infection, injection site erythema, injection site hemorrhage, injection site induration, injection site inflammation, injection site mass, injection site pain, injection site pruritus, injection site urticaria, injection site welt, neck pain, pain, migrane, 15 syncope, tachycardia, vasodilatation, anorexia, diarrhea, gastroenteritis, gastrointestinal disorder, nausea, vomiting, ecchymosis, peripheral edema, arthralgia, agitation, anxiety, confusion, foot drop, hypertonia, nervousness, nystagmus, speech disorder, tremor, vertigo, bronchitis, dyspnea, 20 laryngismus, rhinitis, erythema, herpes simplex, pruritus, rash, skin nodule, sweating, urticaria, ear pain, eye - 16 disorder, dysmenorrheal, urinary urgency, and vaginal moniliasis. As used herein, injection site reaction (ISR) refers to a 5 reaction such as erythema, hemorrhage, induration, inflammation, mass, pain, pruritus, urticaria, and welt that occurs immediately around the site of injection. As used herein, "tolerability" relates to the level of 10 discomfort associated with GA treatment. Tolerability is associated with the frequency and severity of post injection reactions and injection site reactions. Tolerability influences the period that a patient can follow GA treatment. 15 As used herein, the term Gd-enhancing lesions, refers to lesions that result from a breakdown of the blood-brain barrier, which appear in contrast studies using gandolinium contrast agents. Gandolinium enhancement provides information as to the age of a lesion, as Gd-enhancing lesions typically 20 occur within a six week period of lesion formation. As used herein, the term Ti-weighted MRI images refers to an MR-image that emphasizes Ti contrast by which lesions may be visualized. Abnormal areas in a Ti-weigted MRI image are 25 "hypointense" and appear as dark spots. These spots are generally older lesions. As used herein, the term T 2 -weighted MRI image, refers to an MR-image that emphasizes T 2 contrast by which lesions may be 30 visualized. T 2 lesions represent new inflammatory activity. As used herein, the term "unit dosage" refers to physically discrete units suited as single administration dose for a subject to be treated, containing a therapeutically effective - 17 quantity of active compound in association with the required pharmaceutical carrier, e.g., a syringe. As used herein, clinically isolated syndrome (CIS) refers to 1) a 5 single clinical attack suggestive of MS and 2) at least one lesion suggestive of MS. As an example, the patient has at least 1 cerebral lesion detectable by an MRI scan and suggestive of multiple sclerosis. As an additional example the lesion is associated with brain tissue inflammation, myelin 10 sheath damage or axonal damage. As another example the lesion is a demyelinatingwhite matter lesionvisible on brain MRI. In a further example, the white matter lesions are at least 3 mm in diameter. 15 The term "single clinical attack" is used synonymously with "first clinical episode", "first clinical attack", and "first clinical event" which, for example, presents as a clinical episode of optic neuritis, blurring of vision, diplopia, involuntary rapid eye movement, blindness, loss of balance, 20 tremors, ataxia, vertigo, clumsiness of a limb, lack of coordination, weakness of one or more extremity, altered muscle tone, muscle stiffness, spasms, tingling, paraesthesia, burning sensations, muscle pains, facial pain, trigeminal neuralgia, stabbing sharp pains, burning tingling pain, slowing of speech, 25 slurring of words, changes in rhythm of speech, dysphagia, fatigue, bladder problems (including urgency, frequency, incomplete emptying and incontinence), bowel problems (including constipation and loss of bowel control), impotence, diminished sexual arousal, loss of sensation, sensitivity to 30 heat, loss of short term memory, loss of concentration, or loss of judgment or reasoning. As used herein, the criteria, as defined by Poser et al. Neurology, March 1983, 13 (3): 227-230, used to determine if a - 18 subject meets the condition consistent with clinically definite multiple sclerosis (CDMS) are: e Two attacks and clinical evidence of two separate lesions or 5 e Two attacks; clinical evidence of one lesion and paraclinical evidence of another separate lesion. An attack (also referred to as an exacerbation, flare, or relapse,) is defined clinically as the sudden appearance or 10 worsening of a symptom or symptoms of neurological dysfunction, with or without objective confirmation. Clinical evidence of a lesion is defined as signs of neurological dysfunction demonstrable by neurological 15 examination. An abnormal sign constitutes clinical evidence even if no longer present, but was recorded in the past by a competent examiner. Paraclinical evidence of a lesion is defined as the 20 demonstration by means of various tests and procedures of the existence of a lesion of the CNS that has not produced clinical signs but that may or may not have caused symptoms in the past. Such evidence may be derived from the hot-bath test, evoked response studies, neuroimaging, and expert neurological 25 assessment. These tests are considered to be extensions of the neurological examination and not laboratory procedures. As used herein, the term "glatiramoid" refers a complex mixture of the acetate salts of synthetic polypeptides, non 30 uniform with respect to molecular weight and sequence. This invention is illustrated in the Examples section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be - 19 construed to, limit in any way the invention as set forth in the claims which follow thereafter.
- 20 Experimental Details Example 1: A multinational, multicenter, randomized, phase III parallel 5 group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40mg/ml administered three times weekly by subcutaneous injection over placebo in a double-blind design. 10 Methods: The study is designed to select three days a week for injection. Three injections are administered for every seven days and there must be at least one day between each 15 injection. Study Duration: e Screening phase: 1 month * Placebo Controlled (PC) Phase: 12 months of 40mg/ml or 20 matching placebo administered three times weekly by subcutaneous injection. e Open Label (OL) Extension: All subjects will continue treatment with the GA 40mg/ml administered three times a week, until this dose is commercially available for the 25 treatment of relapsing remitting multiple sclerosis (RRMS) patients or until the development of this dose for MS is stopped by the Sponsor. Study Population: 30 Subjects with RRMS Number of Subjects: 1350 subjects - 21 Study Objective(s): To assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40mg/ml administered three times weekly 5 compared to placebo in a double-blind study design. Study Design: Eligible subjects are randomized in a 2:1 ratio (40mg:placebo) and assigned to one of the following three treatment arms: 10 1. 40mg s.c. GA three times weekly (900 subjects) 2.Matching placebo three times weekly (450 subjects) During the PC phase, subjects are evaluated at study sites for a total of 7 scheduled visits at months: -1 (screening), 0 15 (baseline), 1, 3, 6, 9, and 12 (End of PC phase). Subjects successfully completing the study are offered the opportunity to enter into an open label extension in which all subjects will continue treatment with 40mg/ml GA dose. This is 20 done until the 40mg/ml GA dose is commercially available for the treatment of relapsing remitting multiple sclerosis (RRMS) patients or until the development of this dose regimen is stopped by the Sponsor. 25 The termination visit of the PC phase will serve as the baseline visit of the OL phase. This phase will include scheduled visits every 3 months for the first 12 months, then scheduled visits every 6 months and will be completed with a termination visit. 30 During the study, the following assessments are performed (regardless of the treatment assignment) at the specified time points: - 22 e Vital signs are measured at each study visit. * A physical examination is performed at months -1 (screening), 0 (baseline) 6, 12 (end of PC phase) and every 6 months thereafter. In addition, a physical examination 5 will be performed at the termination visit of the OL phase. * The following safety clinical laboratory tests are performed: o Complete blood count (CBC) with differential - at all scheduled visits in the PC phase, and every 12 months 10 thereafter. In addition this test will be performed at the termination visit of the OL phase. o Serum chemistry (including electrolytes, creatinine, urea and liver enzymes) and urinalysis - at all scheduled visits in the PC phase, and every 12 months thereafter. In 15 addition this test will be performed at the termination visit of the OL phase. o Serum P-hCG in women of child-bearing potential is performed at months -1 (screening), 0 (baseline), 12 (end of PC phase), and every 12 months thereafter. In addition 20 this test will be performed at the termination visit of the OL phase. * ECG is performed at months -1 (screening), 0 (baseline), 12 (end of PC phase), and every 12 months thereafter. In addition an ECG will be performed at the termination visit 25 of the OL phase. e Chest X-ray is performed at month -1 (screening) if not performed within 6 months prior to screening visit. * Adverse Events (AEs) are monitored throughout the study. e Concomitant Medications are monitored throughout the study.
- 23 e Neurological evaluations, including Neurostatus [Functional Systems (FS), Expanded Disability Status Scale (EDSS), Ambulation Index (AL)] are performed at months -1 (screening), 0 (baseline), 3, 6, 9, 12 (end of PC phase) and 5 every 6 months thereafter. In addition, a neurological examination are performed at the termination visit of the OL phase. e The general health status is assessed by the EuroQoL (EQ5D) questionnaire at months 0 (baseline) and 12 (end of PC 10 phase). * Additional quality of life parameters are assessed by the WPAI (Work Productivity and Activities Impairment) Questionnaire at month 0 (baseline), 3, 6, 9 and 12 (end of PC phase). 15 e All subjects undergo MRI scans at months 0 (13-7 days prior to baseline visit), 6 and 12 (end of PC phase). Following the results of the PC phase, the Sponsor may decide to perform an MRI scan at the termination visit of the OL phase. 20 e Relapses are confirmed/monitored throughout the study. Ancillary Studies: * Blood samples for determination of anti-GA antibodies are collected for all subjects at months 0 (baseline), 1, 3, 25 6, 9, 12 (end of PC phase), 18 and 24. * Blood samples for evaluation of PBL proliferation in response to GA, as well as other immunological parameters, are collected in a subset of subjects at months 0 (baseline), 1, 3, 6, and 12 (end of PC phase).
- 24 * Blood samples for Pharmacogenetic (PGx) analysis are collected for all subjects twice during the study, preferably at month 0 (baseline) and month 1. 5 The allowed treatment for a multiple sclerosis relapse will be intravenous methylprednisolone 1 gr/day for up to 5 consecutive days. Re-consent criteria 10 In case of a confirmed diagnosis of MS relapse (as defined in the protocol), or in case of an increase in EDSS of 1.5 points or more, sustained for at least 3 months, during the placebo controlled phase, the following actions are taken: e The subject is reminded of the current available MS 15 medications/treatments and the opportunity to terminate the study. e The subject is requested to re-sign an informed consent form if he/she chooses to continue to participate in the study, in the same treatment assignment. 20 The study is closely monitored through the study course by the sponsor's personnel as well as by an external independent data monitoring committee (DMC) in order to ensure subjects' welfare. 25 Inclusion/Exclusion: Inclusion Criteria: e Subjects must have a confirmed and documented MS 30 diagnosis as defined by the Revised McDonald criteria (Ann Neurol 2005: 58:840-846), with a relapsing-remitting disease course.
- 25 e Subjects must be ambulatory with an EDSS score of 0-5.5 in both screening and baseline visits. e Subjects must be in a relapse-free, stable neurological condition and free of corticosteroid treatment 5 [intravenous (IV), intramuscular (IM) and/or per os (PO)] or ACTH 30 days prior to screening (month -1) and between screening (month -1) and baseline (month 0) visits. e Subjects must have had experienced one of the following: o At least one documented relapse in the 12 months 10 prior to screening, or o At least two documented relapses in the 24 months prior to screening, or o One documented relapse between 12 and 24 months prior to screening with at least one documented Ti-Gd 15 enhancing lesion in an MRI performed within 12 months prior to screening. e Subjects must be between 18 and 55 years of age, inclusive. e Women of child-bearing potential must practice an 20 acceptable method of birth control [acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or a double-barrier 25 method (condom or diaphragm with spermicide)]. e Subjects must be able to sign and date a written informed consent prior to entering the study. e Subjects must be willing and able to comply with the protocol requirements for the duration of the study. 30 - 26 Exclusion Criteria: e Subjects with progressive forms of MS. e Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 5 months prior to screening. e Use of immunosuppressive (including Mitoxantrone (Novantrone) or cytotoxic agents within 6 months prior to the screening visit. * Previous use of either natalizumab (Tysabri@) or any 10 other monoclonal antibodies within 2 years prior to screening. e Use of cladribine within 2 years prior to screening. * Previous treatment with immunomodulators (including IFNP la and 1b, and IV Immunoglobulin (IVIg) within 2 months 15 prior to screening. * Previous use of GA or any other glatiramoid. e Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit. 20 e Previous total body irradiation or total lymphoid irradiation. * Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation. * Known human immunodeficiency virus (HIV) positive status. 25 e Pregnancy or breastfeeding. e Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG, abnormal laboratory - 27 tests and chest X-ray. Such conditions may include hepatic, renal or metabolic diseases, systemic disease, acute infection, current malignancy or recent history (5 years) of malignancy, major psychiatric disorder, history 5 of drug and/or alcohol abuse and allergies that could be detrimental according to the investigator's judgment. * A known history of sensitivity to Gadolinium. e Inability to successfully undergo MRI scanning. * A known drug hypersensitivity to mannitol. 10 Route and Dosage Form: e Glatiramer Acetate 40mg in lml for subcutaneous injection in a pre-filled syringe (PFS), administered three times a week. 15 e Matching placebo injection (mannitol in 1ml WFI) for subcutaneous injection in a pre-filled syringe (PFS). Outcome Measures: Primary Outcome Measure: 20 e The total number of confirmed relapses during the 12 month PC phase. Secondary Outcome Measure: e The number of new T 2 lesions at month 12 (end of PC phase) 25 as compared to baseline scan. * The cumulative number of enhancing lesions on Ti-weighted images taken at months 6 and 12 (end of PC phase). * Brain atrophy as defined by the percent brain volume change from baseline to month 12 (end of PC phase). 30 Exploratory Endpoints: The following assessments are presented in an exploratory manner.
- 28 * The time to the first confirmed relapse during the placebo-controlled phase. e The proportion of relapse-free subjects during the placebo-controlled phase. 5 e The total number of confirmed relapses during the placebo-controlled phase requiring hospitalization and/or IV steroids. e The proportion (%) of subjects with confirmed EDSS progression during the placebo-controlled phase 10 (progression of at least 1 EDSS point sustained for at least 3 months). e Change from baseline to month 12 (end of placebo controlled phase) in EDSS Score. e Change from baseline to month 12 (end of placebo 15 controlled phase) in Ambulation Index. e The total volume of T 2 lesions at month 12 (end of placebo-controlled phase) e The number of new hypointense lesions on enhanced Ti scans at month 12 (end of placebo-controlled phase) as compared 20 to the baseline scan. e The total volume of hypointense lesions on enhanced Ti scans at month 12 (end of placebo-controlled phase). * Brain atrophy as defined by the percentage change from baseline to month 12 (end of placebo-controlled phase) in 25 normalized gray matter volume and in normalized white matter volume. e The general health status, as assessed by the EuroQoL (EQ5D) questionnaire. * Assessment of the effect of general health and symptom 30 severity on work, using the work productivity and - 29 activities impairment - General Health (WPAI-GH) questionnaire. Safety and Tolerability Outcome Measures: 5 Safety: e Adverse events e Vital signs * ECG findings 10 e Clinical laboratory parameters Tolerability: * Proportion of subjects (%) who prematurely discontinued from the study, reason of discontinuation and the time to 15 withdrawal. * Proportion of subjects (%) who prematurely discontinued from the study due to AEs and the time to withdrawal. Statistical Considerations: 20 The sample size considerations for the study are based on the following assumptions: * An individual subject's number of confirmed relapses during a one year period reflects a Poisson process with an individual rate of Xi, and this individual subject 25 rates Xi are exponentially distributed with mean 1/0, where 0 is the population's annualized relapse rate. This approach models the total number of confirmed relapses as an Over Dispersed Poisson distribution. e The expected annualized relapse rate in an untreated 30 subject population is 0=0.35 relapses per year.
- 30 e Treatment with 40mg s.c. GA three times weekly reduces the subject population annualized relapse rate by 30% or more when compared to the placebo group. That is, the expected annualized relapse rate of the GA treated 5 populations is 0=0.245 relapses per year or less. In addition, the following are also incorporated in the sample size calculation: 15% of the subjects drop out during the treatment duration. 10 This drop out rate is taken into account in the calculations, as on the average, a subject who drops out of the study contributes 6 months of exposure to the treatment Hochberg's step-up modification to Bonferroni's method is used 15 to maintain the experiment-wise type-I error when comparing multiple treatment arms to placebo, and the p-values for the lAs are calculated using the O'brien-Fleming alpha spending functions. 20 A simulation study accounting for the above underlying assumptions used the Quasi-Likelihood (over-dispersed) Poisson Regression (SAS® PROC GENMOD), revealed that a total of 1350 subjects (900 subjects in the 40mg GA arm, and 450 subjects to the placebo arm) provide approximately 90% power to detect a 25 significant difference in the total number of confirmed relapses as described above. The analysis of the total numbers of confirmed relapses during the study period is based on baseline adjusted Quasi 30 Likelihood (over-dispersed) Poisson Regression. The analysis of the number of new T 2 lesions at month 12 and of the cumulative number of enhancing lesions on Ti-weighted - 31 images taken at months 6 and 12 is based on baseline-adjusted Negative Binomial Regression. The analysis of Brain Atrophy will be based on Analysis of 5 Covariance (ANCOVA). Results Primary Outcome Measure: 10 Treatment with 40mg s.c. GA three times weekly reduces the subject population annualized relapse rate by 30% or more when compared to the placebo group. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA 15 daily administration at reducing the subject population annualized relapse rate. Secondary Outcome Measures: 20 e Treatment with 40mg s.c. GA three times weekly significantly reduces the number of new T 2 lesions at month 12. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing the number of new T 2 lesions at 25 month 12. e Treatment with 40mg s.c. GA three times weekly significantly reduces the cumulative number of enhancing lesions on Ti-weighted images taken at months 6 and 12. 30 Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing the cumulative number of enhancing lesions on Ti-weighted images taken at months 6 and 12.
- 32 e Treatment with 40mg s.c. GA three times weekly significantly reduces brain atrophy as defined by the percent brain volume change from baseline to month 12. Treatment with 40mg s.c. GA three times weekly is at 5 least as effective as 20mg s.c. GA daily administration at reducing brain atrophy as defined by the percent brain volume change from baseline to month 12. Exploratory Endpoints: 10 e Treatment with 40mg s.c. GA three times weekly significantly increases the time to the first confirmed relapse during the placebo-controlled phase. Treatment with 40mg s.c. GA three times weekly is at least as 15 effective as 20mg s.c. GA daily administration at increasing the time to the first confirmed relapse during the placebo-controlled phase. e Treatment with 40mg s.c. GA three times weekly 20 significantly increases the proportion of relapse-free subjects during the placebo-controlled phase. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at increasing the proportion of relapse-free subjects during 25 the placebo-controlled phase. e Treatment with 40mg s.c. GA three times weekly significantly increases the proportion of relapse-free subjects during the placebo-controlled phase. Treatment 30 with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at increasing the proportion of relapse-free subjects during the placebo-controlled phase.
- 33 e Treatment with 40mg s.c. GA three times weekly significantly reduces the total number of confirmed relapses during the placebo-controlled phase requiring hospitalization and/or IV steroids. Treatment with 40mg 5 s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing the total number of confirmed relapses during the placebo controlled phase requiring hospitalization and/or IV steroids. 10 e Treatment with 40mg s.c. GA three times weekly significantly reduces the progression of MRI-monitored disease activity in the patient. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg 15 s.c. GA daily administration at reducing the progression of MRI-monitored disease activity in the patient. e Treatment with 40mg s.c. GA three times weekly significantly reduces the total volume of T 2 lesions at 20 month 12. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing total volume of T 2 lesions at month 12. 25 e Treatment with 40mg s.c. GA three times weekly significantly reduces the number of new hypointense lesions on enhanced Ti scans at month 12 as compared to the baseline scan. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA 30 daily administration at reducing the number of new hypointense lesions on enhanced Ti scans at month 12 as compared to the baseline scan.
- 34 e Treatment with 40mg s.c. GA three times weekly significantly reduces the total volume of hypointense lesions on enhanced Ti scans at month 12. Treatment with 40mg s.c. GA three times weekly is at least as effective 5 as 20mg s.c. GA daily administration at reducing the total volume of hypointense lesions on enhanced Ti scans at month 12. e Treatment with 40mg s.c. GA three times weekly 10 significantly reduces brain atrophy as defined by the percentage change from baseline to month 12 in normalized gray matter volume and in normalized white matter volume. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration 15 at reducing brain atrophy as defined by the percentage change from baseline to month 12 in normalized gray matter volume and in normalized white matter volume. e Treatment with 40mg s.c. GA three times weekly 20 significantly reduces the level of disability as measured by EDSS Score. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing the level of disability as measured by EDSS Score. 25 e Treatment with 40mg s.c. GA three times weekly significantly reduces the proportion (%) of subjects with confirmed EDSS progression during the placebo-controlled phase (progression of at least 1 EDSS point sustained for 30 at least 3 months). Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing proportion (%) of subjects with confirmed EDSS progression during the - 35 placebo-controlled phase (progression of at least 1 EDSS point sustained for at least 3 months). e Treatment with 40mg s.c. GA three times weekly 5 significantly reduces the change from baseline to month 12 (end of placebo-controlled phase) in EDSS Score. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing the change from baseline to month 12 (end of 10 placebo-controlled phase) in EDSS Score. e Treatment with 40mg s.c. GA three times weekly significantly reduces the change from baseline to month 12 (end of placebo-controlled phase) in Ambulation Index. 15 Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing the change from baseline to month 12 (end of placebo-controlled phase) in Ambulation Index. 20 e Treatment with 40mg s.c. GA three times weekly significantly reduces the level of disability as measured by EuroQoL (EQ5D) questionnaire. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing the level of 25 disability as measured by EuroQoL (EQ5D) questionnaire. e Treatment with 40mg s.c. GA three times weekly significantly reduces the level of disability as measured by the work productivity and activities impairment 30 General Health (WPAI-GH) questionnaire. Treatment with 40mg s.c. GA three times weekly is at least as effective as 20mg s.c. GA daily administration at reducing the level of disability as measured by the work productivity - 36 and activities impairment - General Health (WPAI-GH) questionnaire. Discussion 5 A significant drawback to GA therapy is the requirement of daily injections, which can be inconvenient. Moreover, in all clinical trials, injection-site reactions were seen to be the most frequent adverse reactions and were reported by the majority of patients receiving GA. In controlled studies, the 10 proportion of patients reporting these reactions, at least once, was higher following treatment with GA (70%) than placebo injections (37%). The most commonly reported injection-site reactions, which were more frequently reported in GA vs. placebo-treated patients, were erythema, pain, mass, 15 puritus, edema, inflammation and hypersensitivity. However, several obstacles and limitations with potential approaches for addressing the drawbacks exist to current GA therapy. Subcutaneous drug delivery is limited, firstly, by 20 the acceptable injection volume. Typically no more than 1 to 2ml of solution is permitted (Kansara V, Mitra A, Wu Y, Subcutaneous Delivery. Drug Deliv Technol, June 2009; 9(6):38 42). Secondly, the potential exists for drug degradation at the site of injection resulting in reduced bioavailability. 25 Thirdly, based on the physiochemical properties of the drug, potent compounds may become locally trapped in the interstitial space which can lead to further localized irritation, precipitation of the drug and concentration dependent adverse effects (Kansara V, Mitra A, Wu Y, 30 Subcutaneous Delivery. Drug Deliv Technol, June 2009; 9(6):38 42). Finally, due to the complex pharmacokinetic behavior of a drug, variation in the frequency of administration is unpredictable and requires empirical testing. For example, although controlled clinical trials have demonstrated the - 37 efficacy of IFNP-lb in the treatment of MS, patient compliance, efficacy and tolerability are affected by the dosage regimen used. Merely increasing the dose of IFNP-lb is insufficient to increase efficacy, the frequency of 5 administration must also be increased (Luca Durelli, J Neurol (2003) 250 [Suppl 4]). Accordingly, the subject application discloses an effective low frequency dosage regimen of GA administration to patients 10 suffering from a relapsing form of multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. Based on the performance of the dosage regimen in these studies, the administration of three s.c. injections 15 over a period of seven days with at least one day between every injection is also expected to work in the treatment of patients who have experienced a clinically isolated syndrome (CIS). This is based on the fact that the 20mg daily s.c. injection has been shown to work in PCT International 20 Application No. PCT/US2008/013146 (see International Publication No. WO 2009/070298 and also U.S. Patent Application Publication No. US 2009-0149541 Al). It is to be understood that any discussion of public 25 documents, acts, materials, devices, articles or the like included herein is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters were common general knowledge in the field relevant to the present 30 invention as it existed before the priority date of any claim of this application. Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be -38 understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. 5 Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were 0 common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this application.

Claims (54)

1. A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis, said method comprising administering to the human patient three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
2. A method of reducing the frequency of relapses in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and has MRI features consistent with multiple sclerosis comprising administering to the human patient a therapeutically effective dosage regimen of three subcutaneous injections of 1 ml of a pharmaceutical composition comprising 40mg of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection, the regimen being sufficient to reduce the frequency of relapses in the patient.
3. Use of a medicament comprising glatiramer acetate in treating a human patient who is suffering from relapsing remitting multiple sclerosis or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis, wherein the medicament is to be administered in a regimen of three subcutaneous injections of a 40mg dose of glatiramer 40 acetate every seven days with at least one day between each subcutaneous injection.
4. Use of glatiramer acetate in a regimen of three subcutaneous injections of a 40mg dose of glatiramer acetate every seven days with at least one day between each subcutaneous injection for treatment of a human patient who is suffering from relapsing-remitting multiple sclerosis or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis.
5. Use of a medicament comprising glatiramer acetate in treating a human patient who is suffering from relapsing remitting multiple sclerosis or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple sclerosis, wherein the medicament comprises a 40mg dose of glatiramer acetate and wherein the medicament is to be administered by subcutaneous injection in a regimen of subcutaneous injections three times every week with at least one day between each subcutaneous injection, and wherein the medicament is a pharmaceutical composition having a pH in the range of 5.5 to 8.5.
6. Use of glatiramer acetate in a regimen of administration, the regimen comprising a 40mg dose of glatiramer acetate administered by subcutaneous injection three times every week with at least one day between each subcutaneous injection for use in treatment of a human patient who is suffering from relapsing-remitting multiple sclerosis or who has experienced a first clinical episode and is at high risk of developing clinically definite multiple 41 sclerosis, and wherein the glatiramer acetate is administered in a pharmaceutical composition having a pH in the range of 5.5 to 8.5.
7. A method of treatment of a human patient suffering from a relapsing form of multiple sclerosis comprising administration to the human patient of three subcutaneous injections of a 40 mg/ml dose of glatiramer acetate each week so as to treat the human patient.
8. A method of treatment of a human patient suffering from a relapsing form of multiple sclerosis which consists of administering weekly to the human patient on only three days during each week a single subcutaneous injection of a 40mg dose of glatiramer acetate so as to treat the human patient.
9. A method of treatment of a human patient suffering from a relapsing form of multiple sclerosis consisting of subcutaneous injections for at least 6 months with lml of a pharmaceutical composition comprising 40mg of glatiramer acetate on only three days during each week with at least one day without a subcutaneous injection of the pharmaceutical composition between each day on which there is a subcutaneous injection, wherein the pharmaceutical composition is in a prefilled syringe, and wherein the pharmaceutical composition further comprises mannitol and has a pH in the range 5.5 to 7.0.
10. A method of treatment of a human patient who has experienced a first clinical episode suggestive of multiple sclerosis and has at least two MRI lesions suggestive of multiple sclerosis which consists of 42 administering weekly to the human patient on only three days during each week a single subcutaneous injection of a 40mg dose of glatiramer acetate so as to treat the human patient.
11. A method of treatment of a human patient who has experienced a first clinical episode suggestive of multiple sclerosis and has at least two MRI lesions suggestive of multiple sclerosis consisting of subcutaneous injections for at least 6 months with lml of a pharmaceutical composition comprising 40mg of glatiramer acetate on only three days during each week with at least one day without a subcutaneous injection of the pharmaceutical composition between each day on which there is a subcutaneous injection, wherein the pharmaceutical composition is in a prefilled syringe, and wherein the pharmaceutical composition further comprises mannitol and has a pH in the range 5.5 to 7.0.
12. A method of treatment of a human patient suffering from a relapsing form of multiple sclerosis which method is more tolerable than and as effective as administration of 20mg of glatiramer acetate s.c. daily, the method consisting of subcutaneous injections for at least 6 months with lml of a pharmaceutical composition comprising 40mg of glatiramer acetate on only three days during each week with at least one day without a subcutaneous injection of the pharmaceutical composition between each day on which there is a subcutaneous injection, wherein the pharmaceutical composition is in a prefilled syringe, and wherein the pharmaceutical composition further comprises mannitol and has a pH in the range 5.5 to 7.0, so as to 43 treat the human patient as effectively as, but more tolerably than, administration of 20mg of glatiramer acetate s.c. daily, wherein the effect is reduction of relapses.
13. A method of reducing the frequency and severity of post injection reactions and of injection site reactions of glatiramer acetate therapy in a human patient suffering from a relapsing form of multiple sclerosis, the method consisting of subcutaneous injections for at least 4 months with 1ml of a pharmaceutical composition comprising 40mg of glatiramer acetate on only three days during each week with at least one day without a subcutaneous injection of the pharmaceutical composition between each day on which there is a subcutaneous injection, wherein the pharmaceutical composition is in a prefilled syringe, and wherein the pharmaceutical composition further comprises mannitol and has a pH in the range 5.5 to 7.0, so as to reduce the frequency and severity of post injection reactions and of injection site reactions in the human patient relative to administration of 20mg of glatiramer acetate s.c. daily.
14. The method according to any one of claims 9 or 11-13, wherein the subcutaneous injections occur for at least 12 months.
15. The method of claim 1 or claim 2, or the use according to any one of claims 3-6, wherein the human patient is suffering from relapsing-remitting multiple sclerosis.
16. The method of claim 1 or claim 2, or the use according to any one of claims 3-6, wherein the human patient has 44 experienced a first clinical episode and has MRI features consistent with multiple sclerosis.
17. The method according to any one of claims 1, 2, 7, 9, 11 16, or the use according to any one of claims 3-6 or 15 16, wherein during each week or each seven days the subcutaneous injections are on day 1, day 3 and day 5 of such week or seven days; day 1, day 3 and day 6 of such week or seven days; day 1, day 4 and day 6 of such week or seven days; day 2, day 4 and day 6 of such week or seven days; day 2, day 4 and day 7 of such week or seven days; day 2, day 5 and day 7 of such week or seven days; or day 3, day 5 and day 7 of such week or seven days.
18. The method of claim 8 or claim 10, wherein the three days during each week are selected from the group consisting of day 1, day 3 and day 5; day 1, day 3 and day 6; day 1, day 4 and day 6; day 2, day 4 and day 6; day 2, day 4 and day 7; day 2, day 5 and day 7; and day 3, day 5 and day 7.
19. The method according to any one of claims 1 or 7-18, or the use according to any one of claims 3-6 or 15-17, wherein alleviating a symptom or the treatment of the human patient comprises reducing the frequency of relapses.
20. The method according to any one of claims 1 or 7-19, or the use according to any one of claims 3-6, 15-17 or 19, wherein alleviating a symptom or the treatment of the human patient comprises reducing the mean cumulative number of Gd-enhancing lesions in the brain of the patient, reducing the mean number of new T2 lesions in 45 the brain of the patient, reducing the cumulative number of enhancing lesions on Ti-weighted images, increasing the time to a confirmed relapse in the patient, reducing the total number of confirmed relapses in the patient, reducing the progression of MRI-monitored disease activity in the patient, reducing total volume of T2 lesions in the patient, reducing the number of new hypointense lesions on enhanced Ti scans in the patient, reducing the total volume of hypointense lesions on enhanced Ti scans, reducing the level of disability as measured by EDSS Score in the patient, reducing the change in EDSS Score in the patient, reducing the change in Ambulation Index in the patient, reducing the level of disability as measured by EuroQoL (EQSD) questionnaire in the patient, and reducing the level of disability as measured by the work productivity and activities impairment - General Health (WPAI-GH) questionnaire in the patient.
21. The method according to any one of claims 1 or 7-20, or the use according to any one of claims 3-6, 15-17 or 19 20, wherein alleviating a symptom or the treatment of the human patient results in reducing the frequency of relapses in the human patient.
22. The method or use of claim 21, wherein alleviating a symptom or the treatment of the human patient further results in reducing the cumulative number of enhancing lesions on Ti-weighted images of the human patient.
23. The method according to any one of claims 1, 2 or 7-22, or the use according to any one of claims 3-6, 15-17 or 19-22, wherein the glatiramer acetate is present in iml 46 of a pharmaceutical composition in a prefilled syringe for self administration by the human patient.
24. The method according to any one of claims 1, 2 or 7-23, or the use according to any one of claims 3-6, 15-17 or 19-23, wherein the medicament is a pharmaceutical composition in the form of a sterile solution or the glatiramer acetate is present in a pharmaceutical composition in the form of a sterile solution.
25. The method according to any one of claims 1, 2 or 7-24, or the use according to any one of claims 3-6, 15-17 or 19-24, or the glatiramer acetate according to any one of claims 4, 6, 15-17 or 19-24, wherein the patient has not received glatiramer acetate therapy prior to initiation of the subcutaneous injections.
26. The method according to any one of claims 1, 2 or 7-25, or the use according to any one of claims 3-6, 15-17 or 19-25, wherein the frequency of an immediate post injection reaction or the frequency of an injection site reaction is reduced relative to daily subcutaneous administration of 20mg glatiramer acetate.
27. The method according to any one of claims 1, 2 or 7-26, or the use according to any one claims 3-6, 15-17 or 19 26, wherein the severity of an immediate post injection reaction or the severity of an injection site reaction is reduced relative to daily subcutaneous administration of 20mg glatiramer acetate.
28. A method of increasing the tolerability of Glatiramer acetate (GA) treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who 47 has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis, said method comprising reducing a frequency of subcutaneous injections from daily subcutaneous injections of a pharmaceutical composition comprising a 20 mg dose of glatiramer acetate to three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every injection.
29. The method of claim 28, wherein increasing the tolerability of glatiramer acetate treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an immediate post injection reaction.
30. The method according to any one of claims 1, 2 or 7-29, or the use according to any one of claims 3-6, 15-17 or 19-27, wherein the immediate post injection reaction is palpitations, feeling hot, flushing, hot flushes, tachycardia, dyspnoea, chest discomfort, chest pain, non cardiac chest , asthenia, back pain, bacterial infection, chills, cyst, face edema, fever, flu syndrome, infection, injection site erythema, injection site hemorrhage, injection site induration, injection site inflammation, injection site mass, injection site pain, injection site pruritus, injection site urticaria, injection site welt, neck pain, pain, migrane, syncope, tachycardia, vasodilatation, anorexia, diarrhea, gastroenteritis, gastrointestinal disorder, nausea, vomiting, ecchymosis, peripheral edema, arthralgia, agitation, anxiety, confusion, foot drop, hypertonia, nervousness, nystagmus, 48 speech disorder, tremor, vertigo, bronchitis, dyspnea, laryngismus, rhinitis, erythema, herpes simplex, pruritus, rash, skin nodule, sweating, urticaria, ear pain, eye disorder, dysmenorrheal, urinary urgency, or vaginal moniliasis.
31. The method of claim 28, wherein increasing the tolerability of glatiramer acetate treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an injection site reaction.
32. The method according to any one of claims 1, 2 or 7-31, or the use according to any one of claims 3-6, 15-17, 19 27 or 30, wherein the injection site reaction is erythema, hemorrhage, induration, inflammation, mass, pain, pruritus, urticaria, or welt that occurs immediately around the site of injection.
33. Use of glatiramer acetate in the preparation of a medicament for treating relapsing-remitting multiple sclerosis in a human patient suffering from relapsing remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis wherein the administration pattern of the medicament is three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection.
34. Use of glatiramer acetate in the preparation of a medicament for treating relapsing-remitting multiple 49 sclerosis in a human patient suffering from relapsing remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis, wherein the medicament is prepared for an administration pattern of three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection.
35. Use of glatiramer acetate in the preparation of a medicament for increasing the tolerability of Glatiramer acetate (GA) treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis, wherein the administration pattern of the medicament is three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection.
36. Use of glatiramer acetate in the preparation of a medicament for increasing the tolerability of Glatiramer acetate (GA) treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis, wherein the medicament is prepared for an administration pattern of three subcutaneous injections of a 40mg dose of glatiramer 50 acetate over a period of seven days with at least one day between every subcutaneous injection.
37. Glatiramer acetate when used in treating relapsing remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis by three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection.
38. Glatiramer acetate when used in increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis by three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection.
39. The method according to any one of claims 1 or 15-32, or the use according to any one of claims 3-6, 15-17, 19-27, 30, or 32-38, the glatiramer acetate according to claim 37 or 38, wherein the patient determined to be at high risk of developing clinically definite multiple sclerosis is a patient with at least two MRI lesions suggestive of multiple sclerosis.
40. A method of reducing frequency of relapses in a human patient suffering from relapsing-remitting multiple 51 sclerosis, said method comprising administering to the human patient three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection.
41. The method of claim 40, wherein the 40mg dose of glatiramer acetate is in a prefilled syringe for self administration by the human patient.
42. A method of treating a human patient with at least two MRI lesions suggestive of multiple sclerosis who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis, said method comprising administering to the human patient three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection.
43. The method of claim 42, wherein the 40mg dose of glatiramer acetate is in a prefilled syringe for self administration by the human patient.
44. A medicament comprising a 40mg dose of glatiramer acetate when used in reducing frequency of relapses in a human patient suffering from relapsing-remitting multiple sclerosis, wherein the medicament is to be administered in three subcutaneous injections over a period of seven days with at least one day between each subcutaneous injection.
45. Use of glatiramer acetate in a treatment regimen to reduce frequency of relapse in a human patient suffering 52 from relapsing-remitting multiple sclerosis, wherein the treatment regimen comprises three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between each subcutaneous injection.
46. A medicament comprising a 40mg dose of glatiramer acetate when used in treating a human patient with at least two MRI lesions suggestive of multiple sclerosis who has experienced a first clinical episode, wherein the medicament is to be administered in three subcutaneous injections over a period of seven days with at least one day between each subcutaneous injection.
47. Use of glatiramer acetate in a treatment regimen to treat a human patient with at least two MRI lesions suggestive of multiple sclerosis who has experienced a first clinical episode, wherein the treatment regimen comprises three subcutaneous injections of a 40mg dose of glatiramer acetate over a period of seven days with at least one day between each subcutaneous injection.
48. The method according to any one of claims 1, 2, 7-32 or 39-43, or the use according to any one of claims 3-6, 15 17, 19-27, 30, 32-39, 45 or 47, or the glatiramer acetate of any one of claims 37-39, or the medicament according to claim 44 or 46, wherein the glatiramer acetate is present in lml of a pharmaceutical composition wherein the pharmaceutical composition further comprises mannitol, and wherein the pharmaceutical composition has a pH in the range of 5.5 to 7.0. 53
49. The method according to any one of claims 1, 2, 7-32, 39 43 or 48, or the use according to any one of claims 3-6, 15-17, 19-27, 30, 32, 37-39 or 48, or the glatiramer acetate of any one of claims 37-39 or 48, or the medicament according to any one of claims 45 or 47-48, wherein administering of three subcutaneous injections of a 40mg dose of glatiramer acetate to the patient over a period of seven days, with at least one day between every subcutaneous injection, increases a tolerability of the patient to glatiramer acetate treatment by virtue of reducing a frequency of a post injection reaction.
50. The method or use or glatiramer acetate or medicament according to claim 49, wherein the increase in tolerability to glatiramer acetate treatment is an increase relative to a treatment comprising daily administration of a 20mg dose of glatiramer acetate by subcutaneous injection.
51. The method or use or glatiramer acetate or medicament according to claim 49 or 50, wherein the immediate post injection reaction is selected from the group consisting of palpitations, feeling hot, flushing, hot flushes, tachycardia, dyspnoea, chest discomfort, chest pain, noncardiac chest asthenia, back pain, bacterial infection, chills, cyst, face edema, fever, flu syndrome, infection, injection site erythema, injection site hemorrhage, injection site induration, injection site inflammation, injection site mass, injection site pain, injection site pruritus, injection site urticaria, injection site welt, neck pain, pain, migrane, syncope, tachycardia, vasodilatation, anorexia, diarrhea, 54 gastroenteritis, gastrointestinal disorder, nausea, vomiting, ecchyrnosis, peripheral edema, arthralgia, agitation, anxiety, confusion, foot drop, hypertonia, nervousness, nystagmus, speech disorder, tremor, vertigo, bronchitis, dyspnea, laryngismus, rhinitis, erythema, herpes simplex, pruritus, rash, skin nodule, sweating, urticaria, ear pain, eye disorder, dysmenorrheal, urinary urgency, and vaginal moniliasis.
52. The method or use or glatiramer acetate or medicament according to any one of claims 49 to 51, wherein the post-injection reaction occurs immediately around the site of injection.
53. The method according to any one of claims 1, 2, 7-32, 39 43 or 48-52, or the use according to according to any one of claims 3-6, 15-17, 19-27, 30, 32-39, 45 or 47-52, the glatiramer acetate according to any one of claims 37, 38, 39, or 48-52, or the medicament according to any one of claims 44, 46 or 48-52 substantially as described with reference to the accompanying Examples.
54. A pharmaceutical product consisting of unit dosages in a pattern of three unit dosages each consisting of a prefilled syringe containing 40mg/ml glatiramer acetate and mannitol in a pharmaceutical composition having a pH in the range of 5.5 to 7.0.
AU2013203367A 2009-08-20 2013-04-10 Low frequency glatiramer acetate therapy Active AU2013203367C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203367A AU2013203367C1 (en) 2009-08-20 2013-04-10 Low frequency glatiramer acetate therapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61/274,687 2009-08-20
US61/337,612 2010-02-11
AU2010284666A AU2010284666B2 (en) 2009-08-20 2010-08-19 Low frequency glatiramer acetate therapy
AU2013201328A AU2013201328B2 (en) 2009-08-20 2013-03-06 Low frequency glatiramer acetate therapy
AU2013203367A AU2013203367C1 (en) 2009-08-20 2013-04-10 Low frequency glatiramer acetate therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2013201328A Division AU2013201328B2 (en) 2009-08-20 2013-03-06 Low frequency glatiramer acetate therapy

Publications (3)

Publication Number Publication Date
AU2013203367A1 AU2013203367A1 (en) 2013-05-02
AU2013203367B2 true AU2013203367B2 (en) 2015-06-25
AU2013203367C1 AU2013203367C1 (en) 2018-01-18

Family

ID=61005614

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013203367A Active AU2013203367C1 (en) 2009-08-20 2013-04-10 Low frequency glatiramer acetate therapy

Country Status (1)

Country Link
AU (1) AU2013203367C1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Also Published As

Publication number Publication date
AU2013203367A1 (en) 2013-05-02
AU2013203367C1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
US9155776B2 (en) Low frequency glatiramer acetate therapy
AU2013203367B2 (en) Low frequency glatiramer acetate therapy
AU2016100455A4 (en) Low frequency glatiramer acetate therapy
AU2015101564B4 (en) Low frequency glatiramer acetate therapy

Legal Events

Date Code Title Description
CB Opposition lodged by

Opponent name: ALPHAPHARM PTY LTD

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 SEP 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 SEP 2015

ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: (2017) APO 41: DECISION: THE OPPOSITION BY ALPHAPHARM PTY LTD IS SUCCESSFUL ON THE GROUND OF FAIR BASIS. CLAIMS 1, 2, 7, 8, 10, 22, 23, 27, 28, 31 TO 64 AND 66 LACK FAIR BASIS. CLAIM 66 IS NOT FOR A MANNER OF MANUFACTURE. THE OPPOSITION IS UNSUCCESSFUL ON THE GROUNDS OF CLARITY, NOVELTY AND INVENTIVE STEP. YEDA RESEARCH & DEVELOPMENT CO., LTD HAS 2 MONTHS FROM THE DATE OF THIS DECISION TO PROPOSE AMENDMENTS. COSTS ACCORDING TO SCHEDULE 8 AWARDED AGAINST YEDA RESEARCH & DEVELOPMENT CO., LTD.

Opponent name: ALPHAPHARM PTY LTD

Effective date: 20170815

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 AUG 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 AUG 2017

FGA Letters patent sealed or granted (standard patent)